Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/161908
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTan, Chin Hongen_US
dc.contributor.authorChew, Justinen_US
dc.contributor.authorZhang, Liwenen_US
dc.contributor.authorGulyás, Balázsen_US
dc.contributor.authorChen, Christopheren_US
dc.date.accessioned2022-09-26T02:26:11Z-
dc.date.available2022-09-26T02:26:11Z-
dc.date.issued2022-
dc.identifier.citationTan, C. H., Chew, J., Zhang, L., Gulyás, B. & Chen, C. (2022). Differential effects of white matter hyperintensities and regional amyloid deposition on regional cortical thickness. Neurobiology of Aging, 115, 12-19. https://dx.doi.org/10.1016/j.neurobiolaging.2022.03.013en_US
dc.identifier.issn0197-4580en_US
dc.identifier.urihttps://hdl.handle.net/10356/161908-
dc.description.abstractWhite matter hyperintensities (WMH) and β-amyloid (Aβ) accumulation have both been linked to neurodegeneration in Alzheimer's disease (AD). However, the independent effects of global WMH and regional Aβ on the corresponding regional cortical thickness have not been investigated. Here, we evaluated 280 cognitively normal (CN), 450 mild cognitive impairment (MCI), and 63 individuals with AD dementia separately. In CN individuals, only WMH was associated with lower cortical thickness in fronto-temporal regions, independent of regional Aβ deposition in the corresponding cortical regions. In MCI individuals, the spatial pattern of independent WMH associations was predominantly in temporal and cingulate regions, while independent regional Aβ associations were now evident in temporal regions. No regional interactions were found. In non-demented individuals and MCI individuals alone, we found that global WMH, composite regional Aβ burden and cortical thickness in AD-associated regions all independently predicted progression to AD dementia. Our findings suggest that the independent effects of global WMH and regional Aβ on regional cortical thickness are spatially different, converging in temporal regions in MCI individuals.en_US
dc.description.sponsorshipMinistry of Education (MOE)en_US
dc.description.sponsorshipNanyang Technological Universityen_US
dc.language.isoenen_US
dc.relationM40824100en_US
dc.relationM4012193en_US
dc.relation.ispartofNeurobiology of Agingen_US
dc.rights© 2022 Elsevier Inc. All rights reserved.en_US
dc.subjectScience::Medicineen_US
dc.titleDifferential effects of white matter hyperintensities and regional amyloid deposition on regional cortical thicknessen_US
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en_US
dc.contributor.schoolSchool of Social Sciencesen_US
dc.identifier.doi10.1016/j.neurobiolaging.2022.03.013-
dc.identifier.pmid35453034-
dc.identifier.scopus2-s2.0-85128637717-
dc.identifier.volume115en_US
dc.identifier.spage12en_US
dc.identifier.epage19en_US
dc.subject.keywordsAmyloiden_US
dc.subject.keywordsCerebral Cortical Thinningen_US
dc.description.acknowledgementThis study was supported by Nanyang Technological University, Singapore Start-Up Grant M40824100 (CHT) and MOE AcRF Tier 1 M4012193 (CHT). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technolo gies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education.en_US
item.grantfulltextnone-
item.fulltextNo Fulltext-
Appears in Collections:LKCMedicine Journal Articles
SSS Journal Articles

Page view(s)

30
Updated on Feb 4, 2023

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.